Trevi Therapeutics (TRVI) Return on Capital Employed (2019 - 2026)
Trevi Therapeutics' (TRVI) quarterly Return on Capital Employed came in at 28.35% in Q1 2026, up 2044.0% year-on-year from 1.32% in Q1 2025, and down 10.13% quarter-over-quarter from 25.74% in Q4 2025.
Trevi Therapeutics (TRVI) Return on Capital Employed (2019 - 2026) Analysis & Trends
Trevi Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 28.35% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 2044.0% year-over-year to 28.35% in Q1 2026; TTM through Mar 2026 was 28.35%, a 2044.0% increase from a year earlier, with the FY2025 full-year figure at 34.64%, up 2284.0% from the prior year.
- Return on Capital Employed retreated to 28.35% in Q1 2026 per TRVI's latest filing, from 25.74% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 25.7% in Q3 2025 and bottomed at 145.67% in Q1 2022.
- The 5-year median for Return on Capital Employed is 34.93% (2022), against an average of 48.74%.
- Biggest YoY gain for Return on Capital Employed was 11892 bps in 2022; the steepest drop was 6514 bps in 2022.
- Year by year, Return on Capital Employed stood at 26.63% in 2022, then plunged by 47 bps to 39.07% in 2023, then tumbled by 66 bps to 64.9% in 2024, then surged by 60 bps to 25.74% in 2025, then declined by 10 bps to 28.35% in 2026.
- Per Business Quant, the three latest TRVI Return on Capital Employed figures stand at 28.35% (Q1 2026), 25.74% (Q4 2025), and 25.7% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Trevi Therapeutics | 2.50 Bn | 2.50 Bn | - | -28.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.35% |
| Dec 31, 2025 | -25.74% |
| Sep 30, 2025 | -25.70% |
| Jun 30, 2025 | -33.85% |
| Mar 31, 2025 | -48.79% |
| Dec 31, 2024 | -64.90% |
| Sep 30, 2024 | -77.47% |
| Jun 30, 2024 | -62.18% |
| Mar 31, 2024 | -48.62% |
| Dec 31, 2023 | -39.07% |
| Sep 30, 2023 | -33.93% |
| Jun 30, 2023 | -29.85% |
| Mar 31, 2023 | -28.61% |
| Dec 31, 2022 | -26.63% |
| Sep 30, 2022 | -34.93% |
| Jun 30, 2022 | -74.30% |
| Mar 31, 2022 | -145.67% |
| Dec 31, 2021 | -145.56% |
| Sep 30, 2021 | -131.17% |
| Jun 30, 2021 | -106.64% |